Evidence map›Paper›PMID 25607819›Full record

ArticlePloS one2015

Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells.

Craig E Barcus, Elizabeth C Holt, Patricia J Keely, Kevin W Eliceiri, Linda A Schuler

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Dynamics of inflammatory signals within the tumor microenvironment.World journal of experimental medicine · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. AnFrontiers in bioengineering and biotechnology · 2023
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Prolactin: The Third Hormone in Breast Cancer.Frontiers in endocrinology · 2022
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Craig E BarcusDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; Cellular and Molecular Biology Program, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Elizabeth C HoltDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Patricia J KeelyCellular and Molecular Biology Program, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; Department of Cell and Regenerative Biology, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; Laboratory for Cellular and Molecular Biology and Laboratory for Optical and Computational Instrumentation, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Kevin W EliceiriCellular and Molecular Biology Program, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; Laboratory for Cellular and Molecular Biology and Laboratory for Optical and Computational Instrumentation, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
Linda A SchulerDepartment of Comparative Biosciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; Cellular and Molecular Biology Program, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

Matrix density promotes pro-tumorigenic hormone actions in breast cancerR01CA179556 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PONIK, SUZANNE MARIE, SCHULER, LINDA A. · 2014 to 2024
$4.9M
Mechanisms Of Cell Migration On 3D Aligned MatricesR01CA142833 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI FRIEDL, ANDREAS, HAHN, KLAUS M. · 2010 to 2020
$3.4M
Development of The Prairie Technologies MPLSM to image cancer models in vivoR01CA136590 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CAMPAGNOLA, PAUL J, KEELY, PATRICIA J · 2009 to 2013
$2.4M
Prolactin: mammary progenitors and tumor initiating cells in luminal carcinomasR01CA157675 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SCHULER, LINDA A. · 2011 to 2015
$1.5M
Biophysical Regulation of Breast DifferentiationR01CA114462 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KEELY, PATRICIA J · 2010 to 2014
$1.5M
Short-Term Research Training of Veterinary Students in WisconsinT35OD011078 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI BJORLING, DALE EDMOND, JORGENSEN, JOAN S · 2012 to 2025
$1.0M
High collagen density favors pro-tumorigenic prolactin actions in breast cancerF31CA177047 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BARCUS, CRAIG · 2013 to 2015
$88k
NCI NIH HHS F31 CA177047NCI NIH HHS R01 CA114462NCI NIH HHS R01 CA136590NCI NIH HHS R01 CA142833NCI NIH HHS R01 CA157675NCI NIH HHS R01 CA179556NIH HHS T35 OD011078
6 · The paper itself

Abstract

Breast cancers that express estrogen receptor alpha (ERα+) constitute the majority of breast tumors. Estrogen is a major driver of their growth, and targeting ER-mediated signals is a largely successful primary therapeutic strategy. Nonetheless, ERα+ tumors also result in the most breast cancer mortalities. Other factors, including altered characteristics of the extracellular matrix such as density and orientation and consequences for estrogen crosstalk with other hormones such as prolactin (PRL), may contribute to these poor outcomes. Here we employed defined three dimensional low density/compliant and high density/stiff collagen-I matrices to investigate the effects on 17β-estradiol (E2) activity and PRL/E2 interactions in two well-characterized ERα+/PRLR+ luminal breast cancer cell lines in vitro. We demonstrate that matrix density modulated E2-induced transcripts, but did not alter the growth response. However, matrix density was a potent determinant of the behavioral outcomes of PRL/E2 crosstalk. High density/stiff matrices enhanced PRL/E2-induced growth mediated by increased activation of Src family kinases and insensitivity to the estrogen antagonist, 4-hydroxytamoxifen. It also permitted these hormones in combination to drive invasion and modify the alignment of collagen fibers. In contrast, low density/compliant matrices allowed modest if any cooperation between E2 and PRL to growth and did not permit hormone-induced invasion or collagen reorientation. Our studies demonstrate the power of matrix density to determine the outcomes of hormone actions and suggest that stiff matrices are potent collaborators of estrogen and PRL in progression of ERα+ breast cancer. Our evidence for bidirectional interactions between these hormones and the extracellular matrix provides novel insights into the regulation of the microenvironment of ERα+ breast cancer and suggests new therapeutic approaches.

Indexed as

Breast NeoplasmsCell Culture TechniquesCell Line, TumorCell MovementCell ProliferationCollagen Type IEstradiolEstrogen Receptor alphaExtracellular MatrixFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsProlactinReceptors, ProlactinCollagen Type IEstradiolEstrogen Receptor alphaProlactinReceptors, Prolactin

Identifiers

PMID25607819
PMCPMC4301649
OpenAlexW2053731769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.